Photo taken from
Jill Feldman/LinkedIn
May 9, 2024, 14:30
Jill Feldman: Dosing studies are critical!
Jill Feldman, Co-Founder of EGFR Resisters, shared a post on X:
“Dosing studies are critical!
OS and QOL both matter and pts/fam are the ONLY ones who can choose what matters most to THEM Amgen Oncology (and many others) please consider alternate doses while doing further studies
PhRMA, please push MED (minimal effective), NOT MTD.”
Read further.
Source: Jill Feldman/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18